文献速递慢阻肺

SUNSET研究:长期三联治疗慢阻肺患者降阶梯至茚达特罗/格隆溴铵的随机双盲三模拟试验

Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2018-01-01

SUNSET研究纳入非频繁急性加重的中重度慢阻肺患者,比较长期三联治疗直接转换为茚达特罗/格隆溴铵与继续三联治疗26周的疗效与安全性。结果显示撤除吸入糖皮质激素后 trough FEV1 下降 -26 ml(95%CI -53 至 1 ml),置信区间上限超过非劣效界值 -50 ml;中重度急性加重年化率无差异(率比 1.08,95%CI 0.83–1.40)。基线血嗜酸性粒细胞≥300/μl 的患者肺功能损失更大且急性加重风险更高。

要点

  • 非频繁加重慢阻肺患者长期三联治疗后直接降阶梯至茚达特罗/格隆溴铵,肺功能有小幅下降,但未达到预设非劣效界值。
  • 降阶梯后中重度急性加重年化率与继续三联治疗无差异(率比 1.08,95%CI 0.83–1.40)。
  • 基线血嗜酸性粒细胞≥300/μl 的患者降阶梯后肺功能损失更大、急性加重风险更高,可能更受益于三联治疗。

核心结论

  • 在无频繁急性加重的慢阻肺患者中,长期三联治疗直接降阶梯至茚达特罗/格隆溴铵导致肺功能小幅下降,置信区间上限超过非劣效界值 -50 ml,急性加重无差异。
  • 基线血嗜酸性粒细胞≥300/μl 的患者降阶梯后肺功能损失更大且急性加重风险更高,提示这类患者可能更受益于三联治疗。

研究设计与样本

  • 26周随机、双盲、三模拟临床试验,评估非频繁急性加重的中重度慢阻肺患者从长期三联治疗直接转换为茚达特罗/格隆溴铵(110/50 μg 每日一次)或继续三联治疗(噻托溴铵 18 μg 每日一次联合沙美特罗/氟替卡松丙酸酯 50/500 μg 每日两次)。
  • 共随机分配 527 例至茚达特罗/格隆溴铵组,526 例至三联治疗组。
  • 主要终点为 trough FEV1 较基线变化的非劣效性;中重度急性加重为预设次要终点。

主要发现

  • 撤除吸入糖皮质激素后 trough FEV1 下降 -26 ml(95%CI -53 至 1 ml),置信区间上限超过非劣效界值 -50 ml。
  • 中重度慢阻肺急性加重年化率两组无差异(率比 1.08,95%CI 0.83–1.40)。
  • 基线血嗜酸性粒细胞≥300/μl 的患者降阶梯后肺功能损失更大且急性加重风险更高。
  • 两组不良事件相似。

关键数值与推荐

  • 非劣效界值为 trough FEV1 变化 -50 ml。
  • 茚达特罗/格隆溴铵剂量为 110/50 μg 每日一次;噻托溴铵 18 μg 每日一次;沙美特罗/氟替卡松丙酸酯 50/500 μg 每日两次。
  • 基线血嗜酸性粒细胞≥300/μl 与降阶梯后肺功能损失更大及急性加重风险更高相关。

临床怎么用

  • 对于无频繁急性加重的慢阻肺患者,长期三联治疗后可考虑直接降阶梯至茚达特罗/格隆溴铵,但需注意肺功能可能小幅下降。
  • 降阶梯决策前应评估基线血嗜酸性粒细胞水平,≥300/μl 的患者可能更受益于继续三联治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: There are no studies on withdrawal of inhaled corticosteroids in patients on long-term triple therapy in the absence of frequent exacerbations. OBJECTIVES: To evaluate the efficacy and safety of direct de-escalation from long-term triple therapy to indacaterol/glycopyrronium in nonfrequently exacerbating patients with chronic obstructive pulmonary disease (COPD). METHODS: This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/glycopyrronium (110/50 μg once daily) or continuation of triple therapy (tiotropium [18 μg] once daily plus combination of salmeterol/fluticasone propionate [50/500 μg] twice daily) in nonfrequently exacerbating patients with moderate-to-severe COPD. Primary endpoint was noninferiority on change from baseline in trough FEV1. Moderate or severe exacerbations were predefined secondary endpoints. MEASUREMENTS AND MAIN RESULTS: A total of 527 patients were randomized to indacaterol/glycopyrronium and 526 to triple therapy. Inhaled corticosteroids withdrawal led to a reduction in trough FEV1 of -26 ml (95% confidence interval, -53 to 1 ml) with confidence limits exceeding the noninferiority margin of -50 ml. The annualized rate of moderate or severe COPD exacerbations did not differ between treatments (rate ratio, 1.08; 95% confidence interval, 0.83 to 1.40). Patients with ≥300 blood eosinophils/μl at baseline presented greater lung function loss and higher exacerbation risk. Adverse events were similar in the two groups. CONCLUSIONS: In patients with COPD without frequent exacerbations on long-term triple therapy, the direct de-escalation to indacaterol/glycopyrronium led to a small decrease in lung function, with no difference in exacerbations. The higher exacerbation risk in patients with ≥300 blood eosinophils/μl suggests that these patients are likely to benefit from triple therapy. Clinical trial registered with www.clinicaltrials.gov (NCT 02603393).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Chapman KR, Hurst JR, Frent SM, et al. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. Am J Respir Crit Care Med. 2018. PMID: 29779416. doi:10.1164/rccm.201803-0405OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。